A Prospective, Open‐Label, Post Marketing Study of the Safety and Effectiveness of a Hyaluronic Acid and Calcium Hydroxyapatite Hybrid Injectable
Journal of Cosmetic Dermatology · 2025-09 · 24 (9)
DOI: 10.1111/jocd.70430 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cosmetic Dermatology, online erschienen am 15.09.2025. Verfasst von Alessandro Gritti und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dr. Alessandro Gritti Oral and Maxillofacial Surgery, Brescia, Italy. Hauptthemen laut MEDLINE: Hyaluronic Acid, Durapatite, Dermal Fillers, Cosmetic Techniques. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie Inc., AbbVie.
Abstract (Originalsprache)
Background
HA‐CaHA is a hybrid injectable combining hyaluronic acid and calcium hydroxyapatite for dual‐mode facial soft tissue augmentation. HA‐CaHA‐L includes 0.3% lidocaine HCL.
Objective
This prospective, open‐label study evaluated the effectiveness and safety of HA‐CaHA for treating midface volume deficit.
Methods
Adults rated Moderate to Severe on the Allergan Midface Volume Deficit Scale (MFVDS) received HA‐CaHA ( n = 110) or HA‐CaHA‐L ( n = 30) in the cheek (primary injection region) and jawline (optional) areas, with optional touch‐up 2 weeks later. Follow‐up visits occurred at Months 1, 3, 6, 9, and 12. The primary endpoint was the MFVDS responder rate (≥ 1‐grade improvement from baseline) at Month 1. Secondary endpoints were the Global Aesthetic Improvement Scale (GAIS) responder rates and change from baseline on FACE‐Q Satisfaction with Cheeks and Satisfaction with Facial Appearance. Exploratory endpoints were the Allergan Cheek Smoothness Scale (ACSS) scores and 3D photo‐based midface movement tracking. Safety was assessed throughout.
Results
At Month 1, MFVDS responder rate was 82.8%, remaining high through Month 12. The GAIS responder rates were 98.5% (investigator‐rated) and 91.8% (participant‐rated) at Month 1, remaining high through Month 12. FACE‐Q scores improved 33.3 (Cheeks) and 23.8 (Facial Appearance) points at Month 1, remaining high through Month 12. ACSS scores peaked at Months 3 (73.7%) and 6 (69.2%), with corresponding skin movement changes. Most participants (95.7%) experienced mild or moderate ISRs. The most common treatment‐related AEs were injection site pain (11.4%), injection site mass (10.7%), and headache (7.1%).
Conclusions
HA‐CaHA and HA‐CaHA‐L are effective and well‐tolerated for midface soft tissue augmentation, lasting up to 1 year.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dr. Alessandro Gritti Oral and Maxillofacial Surgery, Brescia, Italy.
- Allergan Aesthetics, an AbbVie Company, Lod, Israel.
- Allergan Aesthetics, an AbbVie Company, Marlow, UK.
- Allergan Aesthetics, an AbbVie Company, Irvine, California, USA.
Förderung
- AbbVie Inc.
- AbbVie
Zitieren
APA
Gritti, A., Salomon, M., Elmaleh, L., Kerson, G., & Schumacher, A. (2025). A Prospective, Open‐Label, Post Marketing Study of the Safety and Effectiveness of a Hyaluronic Acid and Calcium Hydroxyapatite Hybrid Injectable. Journal of Cosmetic Dermatology, 24(9). https://doi.org/10.1111/jocd.70430
Vancouver
Gritti A, Salomon M, Elmaleh L, Kerson G, Schumacher A. A Prospective, Open‐Label, Post Marketing Study of the Safety and Effectiveness of a Hyaluronic Acid and Calcium Hydroxyapatite Hybrid Injectable. Journal of Cosmetic Dermatology. 2025;24(9). doi:10.1111/jocd.70430
BibTeX
@article{Gritti2025,
author = {Gritti, Alessandro and Salomon, Malka and Elmaleh, Lea and Kerson, Graeme and Schumacher, Andrew},
title = {A Prospective, Open‐Label, Post Marketing Study of the Safety and Effectiveness of a Hyaluronic Acid and Calcium Hydroxyapatite Hybrid Injectable},
journal = {Journal of Cosmetic Dermatology},
year = {2025},
volume = {24},
number = {9},
doi = {10.1111/jocd.70430}
}
EUVIMED